Objectives The aim of this paper is to describe the properties and development of new pharmaceutical forms for topical treatment of glaucoma. Accordingly, different strategies for delivering antiglaucoma drugs to the target sites - in the front and back of the eye will be described. The paper will also list the advantages as well as the disadvantages of each technique with reference to their possible applicability as future therapies in the clinical environment. Material/Patients and Methods This research used the data obtained by searching literary databases for the themes relevant to the creation of final paper, ranging from general to specialized articles. The data were studied critically considering the development of pharmaceutical forms for topical treatment of glaucoma. Results In order to increase the bioavailability of ophthalmic drugs, various techniques have been developed to extend the contact time between ophthalmic and ocular tissues. Some of the techniques stated below are described in this paper: o Improvement of corneal permeability by chemical and famaceutical modifications (pro-drugs, transmitters, ion pairs, iontophoresis, cyclodextrins) o Increase in drug retention by the vehicle (suspensions, viscous systems, in situ gels) o Improvement in drug retention by using colloidal dispersion systems (liposomes, emulsions, nanoparticles and nanocapsules) Suvremeni farmaceutski oblici za topikalno liječenje glaukoma o Increase in drug retention by solid polymeric matrix and devices (degradable and nondegradable matrices, collagen shields, contact lenses) o Implantable systems There are intensive investigations in the field of development of new drug delivery systems that would further increase the effectiveness of glaucoma therapy. Conclusion The development of new pharmaceutical forms for eye medicines in the treatment of glaucoma is a relatively complex and prolonged process that requires verifaction of appropriate drug delivery, safety of administration, and the assurance of the adequate quality of the developed pharmaceutical formulation. Newly formulated medicines should be biocompatible, non-toxic and with minumum hindering of field of vision. It is also necessary to take into account the correctness of the administration by patients. Current and future research focused on these factors will contribute to the development of new delivery systems for ophthalmic drugs and lead to progression in topical glaucoma treatment.